Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
Researchers discuss the development of effective targeted therapy to manage Group 3 medulloblastomas by targeting α5-GABA-A receptor.
The transcriptional coactivator YAP1 rescued cell viability in KRAS-dependent cells upon suppression of KRAS and was required for KRAS-induced cell transformation.
Investigators find that acute myeloid leukemias with MLL fusions are dependent on CDK6, offering a therapeutic strategy.
BET proteins are critical regulators of the Hedgehog pathway, suggesting that BET inhibitors may be used to treat Hedgehog-driven tumors.
Authors develop a computational approach for automated quantitation of off-target effects in RNAi screening data sets.
Researchers present methods which are specifically designed to handle cancer-related copy-number profiles.
In an effort to identify biomarkers of recurrence for Prostate cancer, researchers performed global RNA sequencing on 106 formalin-fixed, paraffin-embedded prostatectomy samples from 100 patients at three independent sites, defining a 24-gene signature panel.
Researchers use reverse-phase protein arrays to study the proteome and compare it to the genomic and transcriptome analysis of 11 TCGA pan-cancer diseases.
Colon organoid culture functionally validated the microRNA miR-483 as a dominant driver oncogene at the IGF2 (insulin-like growth factor-2) 11p15.5 CRC amplicon, inducing dysplasia in vitro and tumorigenicity in vivo.
Investigators show that knockdown or deletion of Hipk2 in vitro and in vivo inhibits white adipose development and negatively affects metabolism.